Drugs / TBL12
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01302366 | Feb 2011 → Dec 2013 | plasma cell myeloma | NYU Langone Health | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT01096810 | Sep 2008 → Mar 2014 | plasma cell myeloma | Jagannath, Sundar, M.D. | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TBL 12 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01096810 ↗ |
| Known as | sea cucumber extract | “TBL12 sea cucumber extract has been shown to have a number of antitumor properties preclinically, including antiangiogenesis and direct tumor cytotoxicity.” NCT01302366 ↗ |
| Route | Oral | “TBL 12 will be administered orally” NCT01096810 ↗ |